About: Assessing abuse liability during drug development: changing standards and expectations.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assessing abuse liability during drug development: changing standards and expectations. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 23 January 2008

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2008 (ast) наукова стаття, опублікована в січні 2008 (uk) مقالة علمية نشرت في 23 يناير 2008 (ar) scientific article published on 23 January 2008 (en)
publication date	wds:Q37062910-58C773AC-2D6E-4A86-A9F3-1D97BC7103B0
publication date	2008-01-23 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37062910-7764AA01-6E9B-4483-B2CD-A65AF04A6077
language of work or name	English
cites work	wds:Q37062910-11A1B9E0-A8B8-498B-9EAA-9A1933F06E7A wds:Q37062910-296FA460-2BAC-46D7-9068-FF1303C36BD1 wds:Q37062910-3FBAB2D3-3FDD-49A0-8B3C-BE4AC40C040C wds:Q37062910-41402B0D-896A-431B-B087-2C95D03042F9 wds:Q37062910-5023DC88-4EE7-40A5-83FF-638ABC0A446B wds:Q37062910-73C8F838-915B-4E35-BBC6-00517D23EEBA wds:Q37062910-796A01D3-A470-41CE-A7B8-A2CC7CEE2E03 wds:Q37062910-885FC7F4-7F44-44D1-A3A6-CBCFD9A6B293 wds:Q37062910-94DB1F63-72A6-4694-93F3-E5E206FDCF4B wds:Q37062910-E5D3999F-9497-4E28-B898-D157E7ABEC9F wds:Q37062910-F038CC57-E5BB-4DF2-A7E7-DC3E9AE2EC9F
cites work	The Internet as a source of drugs of abuse Principles of drug abuse liability assessment in laboratory animals Guidelines and methodological reviews concerning drug abuse liability assessment Principles of initial experimental drug abuse liability assessment in humans Research design strategies to evaluate the impact of formulations on abuse liability Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol Incorporating the assessment of abuse liability into the drug discovery and development process Assessing abuse liability in clinical trials Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report Perspectives and future on testing for abuse liability in humans Conference on drug formulations and abuse liability
author name string	wds:Q37062910-ADABA47E-E6C1-4640-866C-347B20E745C6
author name string	K A Schoedel
rdfs:label	Assessing abuse liability during drug development: changing standards and expectations. (en) Assessing abuse liability during drug development: changing standards and expectations. (nl) Assessing abuse liability during drug development: changing standards and expectations. (ast)
skos:prefLabel	Assessing abuse liability during drug development: changing standards and expectations. (en) Assessing abuse liability during drug development: changing standards and expectations. (nl) Assessing abuse liability during drug development: changing standards and expectations. (ast)
name	Assessing abuse liability during drug development: changing standards and expectations. (en) Assessing abuse liability during drug development: changing standards and expectations. (nl) Assessing abuse liability during drug development: changing standards and expectations. (ast)
author	wds:Q37062910-8820A6F1-1C19-48D2-B207-2991BF8C3BCF
author	Edward M. Sellers
title	wds:Q37062910-E156A98E-CF35-403E-8BBD-288C63ADCBC6
title	Assessing abuse liability during drug development: changing standards and expectations (en)
page(s)	wds:Q37062910-E8A8F2ED-124C-4C54-BFF6-8F9FDE53DF2A
page(s)	622-626
instance of	wds:Q37062910-202CDF59-D352-4144-AB15-50B68FA62197 wds:Q37062910-d1b2f9de-6bef-4172-82f3-4f9669f2b1bf
instance of	review article scholarly article
PubMed ID	wds:Q37062910-3ED1BBA5-6A32-4703-A088-095082508F89
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18212799
PubMed ID	18212799
published in	wds:Q37062910-AFE83FC4-4A5C-4A93-A99A-5F91C94CBC6C
published in	Clinical Pharmacology & Therapeutics
issue	wds:Q37062910-7911F7FE-7D31-48A5-A43C-4C4AF28DEDAA
volume	wds:Q37062910-1B1DB136-5895-4EE2-B933-497E3DDDFD5F
issue	4
volume	83
DOI	wds:Q37062910-FDAE52E8-218A-4953-97B5-35423F373BC8
DOI	http://dx.doi.org/10.1038/SJ.CLPT.6100492
DOI	10.1038/SJ.CLPT.6100492
ResearchGate publication ID	wds:Q37062910-9297A6C9-35BE-4955-A9A1-542B25FACF5F
ResearchGate publication ID	5638534
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37062910
is cites work of	Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs Abuse liability assessment of tobacco products including potential reduced exposure products Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women Prediction and Prevention of Prescription Drug Abuse: Role of Preclinical Assessment of Substance Abuse Liability Principles of laboratory assessment of drug abuse liability and implications for clinical development Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users Age Moderates Smokers' Subjective Response to Very-Low Nicotine Content Cigarettes: Evidence from a Randomized Controlled Trial. Adolescent smokers' response to reducing the nicotine content of cigarettes: Acute effects on withdrawal symptoms and subjective evaluations Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users Foods are differentially associated with subjective effect report questions of abuse liability Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing Relationship between intranasal cocaine self-administration and subject-rated effects: predictors of cocaine taking on progressive-ratio schedules Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users. A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software